Bone Abstracts

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...

Osteoarthritis is a complex pathogenesis because diverse factors interact causing a process of deterioration of the cartilage and the subchondral bone. Despite the multifactorial nature of the knee osteoarthritis, it is related to a strong genetic component. Determination of molecular genetic causes of osteoarthritis is an actual problem. There are several approaches to assess the contribution of a candidate gene in the pathogenesis of osteoarthritis. The aim of the study was ...

Introduction: Osteoporosis is a global public health problem affecting more than 200 million people worldwide. Osteoporosis has clinical and public health implications because of the mortality, morbidity, and cost of medical care associated with osteoporotic fractures. The World Health Organization (WHO) has defined criteria for assessing bone status by DEXA, which are defined by the T-score, which is the number of standard deviations (SDs) by which a patient’s t...

Owing to their anti-inflammatory effects, steroid therapy using glucocorticoids (GCs) is still part of the treatment of rheumatoid arthritis (RA), despite several severe side effects like glucocorticoid-induced osteoporosis (GIO). Until now the molecular mechanisms underlying the beneficial and side effects of GC therapy are poorly understood. GCs exert their actions via the glucocorticoid receptor (GR) that alters gene expression by either binding as a dimer to GC response el...

Pseudovitamin D-deficiency rickets (PDDR) is a rare autosomal recessive disorder resulting from a defect in renal 25-hydroxyvitamin D 1α-hydroxylase, which is encoded by the CYP27B1 gene. To our best knowledge, 48 mutations of the CYP27B1 gene have been identified so far. In the present study, we investigated CYP27B1 mutations in seven individuals from six separate families and identified nine different mutations: two novel missense mutations (G194R, R259L), three novel a...

Bisphosphonates are the mainstay of medical therapy in the fracturing child with osteoporosis. The majority of the data in children pertains to i.v. pamidronate use in children and adolescents with osteogenesis imperfecta (OI), where pamidronate has been associated with improvements in bone mineral density, cortical thickness, vertebral shape, pain, mobility and height.1 Side-effects of pamidronate including acute phase response to the initial dose and retardation o...

Iisn’t uncommon to encounter patients with both a fragility fracture and only a slightly low BMD value or even normal one. Currently the DXA technology can assess information on trabecular microstructural texture supplementing the standard BMD measurement, using a new method: the trabecular bone score (TBS). In order to check TBS, BMD and their combination to discriminate patients with vertebral fracture, we scanned 946 subjects. The cohort was stratified using the WHO di...

Objective: Evidence for further reduction of nonvertebral fracture (NVFX) beyond 3 years of antiresorptive therapy is limited. Since long-term denosumab (DMAb) treatment is associated with continuous increases in BMD and sustained fracture reduction, we analyzed the influence of femoral neck (FN) BMD after 3 years on NVFX rates.Methods: Long-term subjects received 7 continuous years of DMAb; cross-over subjects received 3 years of placebo (FREEDOM) and 4...

Multiple factors of risk have been described to the osteoporosis (OSP) and fractures in people infected by human immunodeficiency virus (HIV). Antiretroviral treatment has changed the vital prognosis of these patients, nevertheless seems that antiretroviral treatments can cause a greater loss of bone mineral density (BMD). Experts support the use of densitometry screening for HIV-infected postmenopausal women and men older than 50 years.Objectives: To ev...

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...